Christine Lovly on Muck Rack

Christine Lovly

Los Angeles, Nashville
As seen in: Color Research & Application, Nature, Molecular Cancer, Medscape, Healio, HemOnc Today, Cancer Discovery, American Journal of Managed Care, OncLive, Managed Healthcare Executive and
Thoracic Medical Oncologist. Physician Scientist. Division Chief @CityofHope. Dog lover. Believer that kindness counts. Views = my own. @Oncoalert
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Christine

Contact Christine, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

“What I Tell My Patients”: Making Sense of New Treatment Options in EGFR-positive NSCLC

|
By Christine Lovly, Eric K Singhi, Aakash Desai, Fawzi Abu Rous
| Oncology News Central Verified
This transcript has been lightly edited for style and clarity. Eric Singhi, MD: Welcome back to LungCancerRx, a podcast prescribing what truly matters: empowerment, knowledge, and hope. Thanks for joining us again for another special episode. I’m Dr. Eric Singhi. And today we are continuing our prescription for knowledge with a particular focus on what is happening for our patients with EGFR-positive disease, specifically patients who have stage IV or unresectable disease.
Open in Who Shared Issue with article?

Say No to Jargon, Yes to Testing: Oncologists Face Tough Patient Conversations in NSCLC

|
By Christine Lovly, Aakash Desai, Eric K Singhi, Fawzi Abu Rous
| Oncology News Central Verified
Listen On: Amazon | Apple | Spotify Lung Cancer Podcast In Episode 4 of LungCancerRx, Christine Lovly, MD, PhD, shares how she talks with patients about the latest data and key questions that oncologists should be asking. Lung Cancer Podcast In Episode 4 of LungCancerRx, Christine Lovly, MD, PhD, shares how she talks with patients about the latest data and key questions that oncologists should be asking.
Open in Who Shared Issue with article?

Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study

|
By Christine Lovly
| brnw.ch
Published In Journal of Clinical Oncology : JCO.24.00731 History Published online: June 01, 2024 Permissions Request permissions for this article. Clinical trial data can be requested by qualified researchers for use in rigorous, independent scientific research as long as the trials are not part of an ongoing or planned regulatory submission. Sharing of data is subject to protection of patient privacy and respect for the patient's informed consent.
Open in Who Shared Issue with article?
See all 25 licensed articles (55 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified